Insider · CIK 0002005369
Invus Global Management, LLC
Files at LXRX (LEXICON PHARMACEUTICALS, INC.), SRRK (Scholar Rock Holding Corp). First filing Feb 4, 2026, latest Feb 4, 2026.
Invus Global Management, LLC files SEC Form 4 as 10% owner and director at LXRX (LEXICON PHARMACEUTICALS, INC.), and also at SRRK (Scholar Rock Holding Corp). Since Feb 4, 2026, Invus Global Management, LLC has reported 1 open-market buy worth $2.0M and 0 open-market sells worth $0, the latest filed on Feb 4, 2026.
A track record needs three past buys with six months of prices behind them; Invus Global Management, LLC has 0, so none is measured yet.
The newest scored trade: bought $2.0M of LXRX on Feb 2, 2026, filed Feb 4, 2026, scored 56 (moderate). In the last 12 months: 1 buy worth $2.0M and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
LXRX: LEXICON PHARMACEUTICALS, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 56Moderate | LEXICON PHARMACEUTICALS, INC. | $2.0M 1,538,462 shares | - | - |
Transactions
Every row this insider has filed, 6 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 11, 2025 | SRRK Scholar Rock Holding Corp | XIn-the-money exercise Common Stock | +1,575,008 | $7.35 | $12M | 10,825,013 | Feb 6, 2026 |
| Dec 11, 2025 | SRRK Scholar Rock Holding Corp | XIn-the-money exercise Warrant (right to buy)derivative | -1,575,008 | $0.00 | $0 | 0 | Feb 6, 2026 |
| Feb 2, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | AGrant or award Common Stockindirect: See Footnotes | +18,553,846 | $1.30 | $24M | 154,734,327 | Feb 4, 2026 |
| Feb 2, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | AGrant or award Common Stockindirect: See Footnotes | +3,846,154 | $1.30 | $5.0M | 7,362,368 | Feb 4, 2026 |
| Feb 2, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | POpen-market purchase Common Stockindirect: See Footnotes | +1,538,462 | $1.30 | $2.0M | 1,538,462 | Feb 4, 2026 |
| Feb 2, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | AGrant or award Series B Convertible Preferred Stockindirect: See Footnotes | +367,145 | $65.00 | $24M | 367,145 | Feb 4, 2026 |
Questions about Invus Global Management, LLC
Answered from the filings on this page, as of the latest one.
Is Invus Global Management, LLC buying or selling?
In the last 12 months Invus Global Management, LLC reported 1 open-market buy worth $2.0M and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $2.0M of LXRX on Feb 2, 2026. Grants, option exercises and tax withholding are not counted.
How did Invus Global Management, LLC's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Invus Global Management, LLC has 0.
Where does Invus Global Management, LLC file Form 4?
Invus Global Management, LLC has filed Form 4 at LXRX (LEXICON PHARMACEUTICALS, INC.); SRRK (Scholar Rock Holding Corp). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.